论文部分内容阅读
自1991年4月,质子泵抑制剂(PPI)奥美拉唑om-eprazolel)在日本临床应用以来,已成为当今消化性溃疡的热门话题。许多临床医生已经用PPI 治疗消化性溃疡,其优点是十分明显的。由于PPI 间世,消化性溃疡的治疗期限,与H:受体阻断剂相比大致减少一半。但是,这种强力的抗溃疡药物也不是o 没有何题,其一是ECL 细胞(entero chromaffin-like cell)增生并进而有发生肿瘤的危险性;另一重要问题是,应用PPI 这样强力的酸分泌抑制剂对溃疡有再发的影响,即高效的促进愈合作用可能会增加溃疡的再发。
Since April 1991 proton pump inhibitor (PPI) om-eprazolel has become a hot topic in today’s peptic ulcer clinical use in Japan. Many clinicians have used PPI for the treatment of peptic ulcer, the advantage is obvious. Due to PPI intercourse, peptic ulcer treatment period, and H: receptor blockers compared to roughly halved. However, this powerful anti-ulcer drug is not o no problem, one is the proliferation of ECL cells (entero chromaffin-like cells) and thus the risk of tumor; the other important issue is the application of PPI such a powerful acid Secretion inhibitors have a secondary effect on ulceration, that is, efficient promotion of healing may increase the recurrence of ulcers.